Lipigon Pharmaceuticals AB (ST:LPGO) — Market Cap & Net Worth
Market Cap & Net Worth: Lipigon Pharmaceuticals AB (LPGO)
Lipigon Pharmaceuticals AB (ST:LPGO) has a market capitalization of $163.02K (Skr1.51 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30868 globally and #735 in its home market, demonstrating a -35.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lipigon Pharmaceuticals AB's stock price Skr0.00 by its total outstanding shares 605933743 (605.93 Million). Analyse Lipigon Pharmaceuticals AB (LPGO) cash flow conversion to see how efficiently the company converts income to cash.
Lipigon Pharmaceuticals AB Market Cap History: 2021 to 2026
Lipigon Pharmaceuticals AB's market capitalization history from 2021 to 2026. Data shows change from $423.85 Million to $163.02K (-79.94% CAGR).
Index Memberships
Lipigon Pharmaceuticals AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.00% | #257 of 281 |
Weight: Lipigon Pharmaceuticals AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lipigon Pharmaceuticals AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lipigon Pharmaceuticals AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.73x
Lipigon Pharmaceuticals AB's market cap is 0.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $423.85 Million | $3.18 Million | -$41.12 Million | 133.29x | N/A |
| 2022 | $51.51 Million | $390.00K | -$37.67 Million | 132.09x | N/A |
| 2023 | $28.10 Million | $16.41 Million | -$12.13 Million | 1.71x | N/A |
| 2024 | $7.53 Million | $10.29 Million | -$25.26 Million | 0.73x | N/A |
Competitor Companies of LPGO by Market Capitalization
Companies near Lipigon Pharmaceuticals AB in the global market cap rankings as of May 4, 2026.
Key companies related to Lipigon Pharmaceuticals AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Lipigon Pharmaceuticals AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Lipigon Pharmaceuticals AB's market cap moved from $423.85 Million to $ 163.02K, with a yearly change of -79.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr163.02K | -70.93% |
| 2025 | Skr560.79K | -92.55% |
| 2024 | Skr7.53 Million | -73.23% |
| 2023 | Skr28.10 Million | -45.44% |
| 2022 | Skr51.51 Million | -87.85% |
| 2021 | Skr423.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Lipigon Pharmaceuticals AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $163.02K USD |
| MoneyControl | $163.02K USD |
| MarketWatch | $163.02K USD |
| marketcap.company | $163.02K USD |
| Reuters | $163.02K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more